Difference between revisions of "Team:UiOslo Norway"
Markushovd (Talk | contribs) |
Markushovd (Talk | contribs) |
||
| Line 1: | Line 1: | ||
{{:Team:UiOslo_Norway/Head}} | {{:Team:UiOslo_Norway/Head}} | ||
{{:Team:UiOslo_Norway/Header}} | {{:Team:UiOslo_Norway/Header}} | ||
| − | |||
<html> | <html> | ||
<head> | <head> | ||
| Line 11: | Line 10: | ||
width: 60%; | width: 60%; | ||
margin-top: 10px; | margin-top: 10px; | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
} | } | ||
| Line 47: | Line 24: | ||
<img class="front" src="https://static.igem.org/mediawiki/2018/3/33/T--UiOslo_Norway--Concept.png" alt="Concept graphic"> | <img class="front" src="https://static.igem.org/mediawiki/2018/3/33/T--UiOslo_Norway--Concept.png" alt="Concept graphic"> | ||
| − | <h3 style="text-align: center; margin-left: auto; margin-right: right;"> | + | <h3 style="text-align: center; margin-left: auto; margin-right: right;">UiOslo_Norway</h3> |
| − | <p style="text-align:justify;"> During their lifetime 75 % of women will experience a <em>Candida albicans</em> | + | <h3 style="text-align:center;">Gold<i style="color: gold;"class="fas fa-medal"></i>Awarded Best Diagnostic Project<i style="color: gold;"class="fas fa-medal"></h3> |
| + | <h3 style="text-align:center;">Gold<i style="color: gold;"class="fas fa-medal"></i>Nominated for Best Presentation<i style="color: gold;"class="fas fa-medal"></h3> | ||
| + | <h3 style="text-align:center;">Gold<i style="color: gold;"class="fas fa-medal"></i>Gold Medal<i style="color: gold;"class="fas fa-medal"></h3> | ||
| + | |||
| + | <p style="text-align:justify;"> During their lifetime 75% of women will experience a <em>Candida albicans</em> infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by <em>C. albicans</em>. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult. | ||
</p> | </p> | ||
| − | <p | + | <p>Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for <em>C. albicans</em> infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on <em>C. albicans</em> specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of <em>C. albicans</em> DNA. |
</p> | </p> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
| + | <!--End of container --> | ||
| − | + | <div style="padding-bottom: 100px;"></div> | |
| − | + | ||
| − | </div> | + | |
| − | + | ||
</body> | </body> | ||
</html> | </html> | ||
| + | {{:Team:UiOslo_Norway/Footer}} | ||
Revision as of 15:09, 2 November 2018
Fast detection of vulvovaginal Candida albicans infections using CRISPR/dCas9
UiOslo_Norway
GoldAwarded Best Diagnostic Project
GoldNominated for Best Presentation
GoldGold Medal
During their lifetime 75% of women will experience a Candida albicans infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by C. albicans. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult.
Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for C. albicans infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on C. albicans specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of C. albicans DNA.